# A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

> **NCT00845026** · PHASE2 · COMPLETED · sponsor: **Denovo Biopharma LLC** · enrollment: 261 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** LY2140023
- **DRUG:** aripiprazole
- **DRUG:** olanzapine
- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00845026
- **Lead sponsor:** Denovo Biopharma LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-12
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00845026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00845026, "A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00845026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*